Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED), with a novel portfolio of neonatal Fc receptor (FcRn) inhibitors including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases. With approximately $888 million in cash and investments as of October 2025, the company expects to fund its current business plans through profitability, supported by anticipated milestone payments and future commercial revenues.
Cyborg Score Rationale
REVEAL-1 topline data in active TED is on track for Q1 2026 and REVEAL-2 topline data in chronic TED is on track for Q2 2026. Strong balance sheet and multiple near-term regulatory catalysts position the company well, though execution risk remains on clinical and regulatory approvals.
Top Insights
Veligrotug BLA accepted for thyroid eye disease with PDUFA target action date of June 30, 2026 under Priority Review, with commercial preparations on track
VRDN-008 showed a longer half-life and more sustained IgG reduction versus efgartigimod in a head-to-head study in non-human primates
Cash, cash equivalents, and marketable securities were $874.7 million as of December 31, 2025, compared with $717.6 million as of December 31, 2024
R&D expenses for 2025 were $338.9 million, compared with $238.3 million for 2024, driven by increased clinical trials and manufacturing activities
Named Competitors
Efgartigimod — FcRn inhibitor approved for myasthenia gravis and CIDP
Thyroid Eye Disease Treatments — Anti-IGF-1R antibodies and complement inhibitors in development/approval
FcRn Inhibitors — Competing candidates in clinical development for multiple autoimmune indications
Recent Developments
(February 2026) Reported 2025 full-year financial results with $874.7M cash position and advanced VRDN-008 into Phase 1 clinical trial
(January 2026) FDA accepted BLA for veligrotug with PDUFA target action date of June 30, 2026; EMA MAA submitted
(January 2026) VRDN-008 IND cleared with Phase 1 clinical trial now enrolling participants
Open the full interactive Viridian Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.